#1 Clinical Trials Search in Europe

Ulotaront

Ulotaront, also known as SEP-363856, is an investigational drug currently being studied in clinical trials for various mental health conditions. This article explores the ongoing research on Ulotaront’s effectiveness and safety in treating major depressive disorder, generalized anxiety disorder, and schizophrenia. These trials aim to provide valuable insights into the potential benefits of this new medication for patients struggling with these challenging mental health disorders.

Table of Contents

What is Ulotaront?

Ulotaront, also known by its research code SEP-363856, is a new medication being developed for the treatment of various mental health disorders[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety. Ulotaront is available in tablet form and is taken orally[2].

What Conditions Does Ulotaront Treat?

Ulotaront is being studied for the treatment of several mental health conditions:

  • Major Depressive Disorder (MDD): Ulotaront is being investigated as an additional treatment for adults with MDD who haven’t responded adequately to other antidepressants[1].
  • Generalized Anxiety Disorder (GAD): Clinical trials are evaluating Ulotaront’s effectiveness in treating adults with GAD[2].
  • Schizophrenia: Researchers are studying Ulotaront’s potential in treating acute psychotic symptoms in patients with schizophrenia[3].

How Does Ulotaront Work?

While the exact mechanism of action is not fully explained in the provided information, Ulotaront (SEP-363856) appears to be a novel medication with a unique way of working. It’s not classified as a typical antidepressant or antipsychotic, which suggests it may have a different approach to treating mental health disorders[1][2][3]

Dosage and Administration

The dosage of Ulotaront varies depending on the condition being treated:

  • For Major Depressive Disorder: Flexible doses ranging from 50 to 75 mg per day are being studied[1].
  • For Generalized Anxiety Disorder: Doses between 50 and 75 mg per day are being evaluated[2].
  • For Schizophrenia: Fixed doses of 50 and 75 mg per day are being tested[3].

Ulotaront is taken orally, typically once daily. The exact dosing schedule and duration of treatment may vary based on the specific condition and individual patient factors[1][2][3].

Efficacy of Ulotaront

The effectiveness of Ulotaront is currently being evaluated in clinical trials. Researchers are using various scales to measure its efficacy:

  • For Major Depressive Disorder: The Montgomery-Åsberg Depression Rating Scale (MADRS) is being used to assess changes in depression symptoms[1].
  • For Generalized Anxiety Disorder: The Hamilton Anxiety Rating Scale (HAM-A) is being utilized to measure anxiety symptom improvement[2].
  • For Schizophrenia: The Positive and Negative Syndrome Scale (PANSS) is being employed to evaluate changes in psychotic symptoms[3].

Additionally, the Clinical Global Impression-Severity (CGI-S) scale is being used across all conditions to assess overall illness severity and improvement[1][2][3].

Safety and Side Effects

As Ulotaront is still in clinical trials, comprehensive safety information is not yet available. However, researchers are closely monitoring various safety aspects, including:

  • Adverse events (side effects)
  • Physical examinations (including body weight and waist circumference)
  • Vital signs (blood pressure, heart rate, and body temperature)
  • Electrocardiograms (ECGs)
  • Clinical laboratory assessments (blood tests)

Additional safety measures being evaluated include assessments for suicidal thoughts and behaviors, movement disorders, and effects on sleep and sexual function[1].

Ongoing Research

Ulotaront is currently in Phase 2/3 clinical trials, which means it’s in the later stages of testing but not yet approved for general use. These trials are designed to further evaluate its effectiveness and safety in larger groups of patients[1][2][3].

It’s important to note that while initial results may be promising, Ulotaront is still an investigational drug. More research is needed before it can be considered for approval by regulatory agencies for widespread use in treating mental health disorders.

Condition Trial Phase Dosage Primary Outcome Measure Key Eligibility Criteria
Major Depressive Disorder Phase 2/3 50-75 mg/day Change in MADRS total score Adults 18-65, MDD diagnosis, inadequate response to 1-3 antidepressants
Generalized Anxiety Disorder Phase 2/3 50-75 mg/day Change in HAM-A total score Adults 18-65, GAD diagnosis, HAM-A score criteria
Schizophrenia Phase 2/3 50 and 75 mg/day Change in PANSS total score Adults 18-65, schizophrenia diagnosis, acute psychotic symptoms

FAQ

  • What is Ulotaront? Ulotaront, also known as SEP-363856, is an investigational drug being studied for the treatment of various mental health conditions, including major depressive disorder, generalized anxiety disorder, and schizophrenia.
  • What conditions is Ulotaront being tested for? Ulotaront is currently being tested in clinical trials for major depressive disorder (MDD), generalized anxiety disorder (GAD), and schizophrenia.
  • How is Ulotaront administered? Ulotaront is administered orally in tablet form. The dosage varies depending on the specific trial and condition being studied, but typically ranges from 25 to 75 mg per day.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the efficacy and safety of Ulotaront compared to placebo in treating the targeted mental health conditions. Researchers are measuring improvements in symptoms using various rating scales specific to each disorder.
  • Who can participate in these clinical trials? Eligibility criteria vary for each trial, but generally include adults aged 18-65 with a confirmed diagnosis of the targeted mental health condition. Participants must meet specific symptom severity criteria and be willing to comply with study procedures. Some trials may have additional inclusion or exclusion criteria based on medical history or previous treatments.

Ongoing Clinical Trials on Ulotaront

  • Testing Ulotaront Added to Antidepressants for Adults with Major Depressive Disorder Who Did Not Respond Well to Initial Treatment

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Hungary Poland Spain

  • Study on the Effectiveness and Safety of Ulotaront for Adults with Generalized Anxiety Disorder

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Estonia Finland Slovakia Spain Sweden

  • Study on the Effectiveness and Safety of SEP-363856 for Patients with Acute Schizophrenia Symptoms

    Not recruiting

    1 1
    Investigated drugs:
    Romania

Glossary

  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities, which significantly impact daily functioning.
  • Generalized Anxiety Disorder (GAD): A mental health disorder characterized by excessive, persistent worry about various aspects of life, often interfering with daily activities.
  • Schizophrenia: A severe mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior.
  • PANSS: Positive and Negative Syndrome Scale, a medical scale used to measure symptom severity in patients with schizophrenia.
  • MADRS: Montgomery-Åsberg Depression Rating Scale, a ten-item diagnostic questionnaire used to measure the severity of depressive episodes.
  • HAM-A: Hamilton Anxiety Rating Scale, a psychological questionnaire used to rate the severity of a patient's anxiety.
  • CGI-S: Clinical Global Impression-Severity scale, a 7-point scale used by healthcare professionals to assess the severity of a patient's illness.
  • Placebo: A substance with no active therapeutic effect, used as a control in clinical trials to test the effectiveness of new medications.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Adjunctive therapy: An additional treatment used together with the primary treatment to maximize its effectiveness.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-ulotaront-as-an-additional-treatment-for-adults-with-major-depressive-disorder/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ulotaront-for-adults-with-generalized-anxiety-disorder/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sep-363856-for-patients-with-acute-schizophrenia-symptoms/